Cubist touts mid-stage data; Covance, Sanofi negotiating sale of two research sites;

 @FiercePharma: Journal questions independence of key Crestor trial. Article | Follow @FiercePharma

> Cubist says that its mid-stage study of CXA-101 hits its endpoints for the treatment of complicated urinary tract infections. Cubist is developing CXA-201--a combination of CXA-101 and the beta-lactamase inhibitor tazobactam--as a first-line IV therapy for the treatment of serious Gram-negative bacterial infections in the hospital. Cubist release

> SuperGen says that a late-stage trial of Dacogen in elderly AML patients failed to hit its primary endpoint. But even though researchers couldn't produce data demonstrating "statistically significant superiority," SuperGen's partner Eisai will see if the survival trend they tracked is sufficient to warrant an approval. Story

> Chelsea Therapeutics plans to hand over more data on its experimental rheumatoid arthritis therapy--CH-4051--to the FDA in late July after the agency raised questions about elevated enzyme levels seen in some patients taking the drug. Report

> Sanofi-Aventis says that it is in exclusive talks with Covance regarding the sale of two research sites in Europe. Sanofi flagged its intention to sell the preclinical research sites last year when it restructured its R&D ops. Story

> The FDA has granted Tarix Pharmaceuticals' TXA127 its Orphan Drug designation as a treatment to enhance engraftment in patients receiving a stem cell transplant. Tarix release

> Mela Sciences is selling 2.2 million shares for $7.50 each and plans to use the money to back its application for a skin cancer screening device. Report

And Finally... Desert bats reduce water loss by changing the make-up of their skin, allowing them to thrive in some of the world's most inhospitable environments. Article

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.